<DOC>
	<DOCNO>NCT01473836</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy safety Japanese adult subject Intra-abdominal/Pelvic infection receive Metronidazole IV 1,500-2,000 mg/day combination ceftriaxone sodium .</brief_summary>
	<brief_title>A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>16 year age old . Diagnosed intraabdominal infection pelvic inflammatory disease . Can obtain specimen bacteriological efficacy assessment . Known suspected hypersensitivity , intolerance contraindication Metronidazole , Ceftriaxone sodium , cephem antibiotic . Severe renal dysfunction ( creatinine clearance &lt; 30 mL/min . ) Reference : CockcroftGault calculation formula . Hepatic dysfunction ( AST , ALT , total bilirubin &gt; 3 time upper limit normal range value ) . Severe underlying disease ; patient drug clinical evaluation difficult confounding disease .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Metronidazole</keyword>
	<keyword>intra-abdominal infection</keyword>
	<keyword>pelvic inflammatory disease</keyword>
	<keyword>anaerobe</keyword>
</DOC>